

Special Issue

Viral Hepatitis and Hepatocellular Carcinoma

Message from the Guest Editor

'Viral hepatitis' is a broad term to describe liver damage due to hepatitis virus (A, B, C, D and E) infection. Chronic hepatitis can lead to complications such as cirrhosis, liver failure and liver cancer, especially hepatocellular carcinoma (HCC). Hepatitis B and C virus (HBV and HCV) infections are leading cause of HCC worldwide. A safe and effective vaccine against HBV is now available.

There is no vaccine for HCV however, a major advance in the liver field in last 5 years has been the introduction of direct acting antivirals (DAAs) targeting HCV infection. HCC is a stepwise process and involves a combination of genetic and epigenetic alterations. Hence, in this special issue I invite you to submit original articles, case reports or review articles to advance our existing knowledgebase regarding (i) viral hepatitis prevention or treatment, (ii) screening of chronic hepatitis patients to assess HCC development, (iii) molecular pathogenesis of viral hepatitis-related HCC development and (iv) novel treatment strategies for viral hepatitis-related HCC.

Guest Editor

Dr. Ruchi Shukla

Biosciences Institute, Newcastle University, Newcastle upon Tyne NE2 4HH, UK

Deadline for manuscript submissions

closed (31 August 2021)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.5
CiteScore 7.7
Indexed in PubMed



mdpi.com/si/54944

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.5
CiteScore 7.7
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X), founded in 2013, now has a firm history of publishing peer-reviewed, state-of-the-art research papers on vaccines and vaccination in the broadest sense. Areas covered include, but are not limited to, novel and emerging vaccine technologies, building on in-depth knowledge of what constitutes a protective immune response. These can be new vaccines for old diseases, or old vaccines for new diseases. Vaccines against cancer and autoimmune diseases explicitly are also within the scope of the journal. Because public opinion and even government policies towards vaccines and vaccination have changed, vaccine policy and public health issues are major concerns. Climate change will also have an impact on the spread of infectious diseases, and thus also on vaccine and vaccination policies worldwide.

Editor-in-Chief

Prof. Dr. Ger Rijkers

Department of Health, Cognition and Behavior, University College
Roosevelt, 4331 CB Middelburg, The Netherlands

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Infectious Diseases)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.1 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).